Please visit our MS learning channel on Youtube, which provides hundreds of topics from our education programs, that were video-recorded and archived here: www.youtube.com/msviewsandnews -- Be empowered with MS news by registering with us: www.register.msviewsandnews.org

joomla ecommerce template -- Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

============================================================

Saturday, October 10, 2015

Ocrelizumab Proven Effective In Multiple Sclerosis Treatment for Primary Progressive MS (PPMS)

Successful clinical trial results by Bay Area researchers was released Thursday on a new drug that shows promise to become the first drug to treat a devastating progressive form of multiple sclerosis (MS). Roche Holding AG’s Genetech unit announced that the experimental drug ocrelizumab proved effective in three studies against MS, reports The Wall Street Journal. The findings in the late-phase trials of ocrelizumab find that the drug greatly reduces symptoms for progressive MS as well as a more common form of the degenerative disease, known as relapsing and remitting multiple sclerosis, which affects nearly 85 percent of MS patients.



Ocrelizumab Proven Effective In Multiple Sclerosis Treatment


Continue Reading


~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
MS Views and News helps to provide information for all affected by MS
Keep up to date with the news and information we provide 
by signing up by clicking here
.===================================

No comments: